The biggest challenge for scientists working on genome engineering, according to Josh Lehrer, M.D., CEO of the newly announced Graphite Bio, is targeting DNA at a specific location and inserting new, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Graphite Bio dosed the first ...
Graphite Bio has filed to raise up to $100 million in an IPO. The money will support the development of gene editing drugs for sickle cell disease, X-linked severe combined immunodeficiency syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results